Neurocrine Biosciences
NBIX
392 hedge funds and large institutions have $9.56B invested in Neurocrine Biosciences in 2019 Q4 according to their latest regulatory filings, with 109 funds opening new positions, 137 increasing their positions, 103 reducing their positions, and 41 closing their positions.
166% more first-time investments, than exits
New positions opened: 109 | Existing positions closed: 41
65% more call options, than puts
Call options by funds: $93.9M | Put options by funds: $56.8M
33% more repeat investments, than reductions
Existing positions increased: 137 | Existing positions reduced: 103
18% more capital invested
Capital invested by funds: $8.09B → $9.56B (+$1.48B)
18% more funds holding
Funds holding: 333 → 392 (+59)
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
1.37% less ownership
Funds ownership: 98.02% → 96.65% (-1.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$77M |
| 2 |
BlackRock
New York
|
+$68.6M |
| 3 |
State Street
Boston,
Massachusetts
|
+$65.5M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$58.7M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$138M |
| 2 |
Janus Henderson Group
London,
|
-$118M |
| 3 |
HM
HealthCor Management
New York
|
-$71.9M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$68.6M |
| 5 |
O
OrbiMed
New York
|
-$66.9M |
NBIX Hedge Fund Activity: Q4 2019 in Review
392 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2019, worth a combined $9.56B — up 18% from $8.09B a quarter earlier.
Buyers outnumbered sellers: 109 funds opened new NBIX positions and 41 closed out — a net gain of 68 holders — while 137 added to existing stakes and 103 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $77M. The largest seller was Fidelity Investments, cutting an estimated $138M.
- 392 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2019, up from 333 in Q3 2019.
- Funds reported $9.56B of Neurocrine Biosciences stock for Q4 2019, up 18% quarter-over-quarter.
- 109 funds opened new Neurocrine Biosciences positions in Q4 2019 and 41 closed out, a net change of +68 holders.
- The largest Neurocrine Biosciences buyer in Q4 2019 was Renaissance Technologies, an estimated $77M added.
- The largest Neurocrine Biosciences seller in Q4 2019 was Fidelity Investments, an estimated $138M sold.
Based on aggregated 13F filings for Q4 2019.